Group structure
2 companies in 2 countries
Canada1
United States1
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Medicines
Every medicine of every company in the group, current ones first.
1–25 of 32
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| CUVPOSA1 mg / 5 ml · Solution | Glycopyrronium | Canada | Marketed | 2018 |
| GLEOLAN1.5 g / vial · Powder For Solution | Aminolevulinic acid | Canada | Marketed | 2021 |
| GRAFAPEX1gm/vial | 5gm/vial · Powder | Treosulfan | United States | Marketed | 2025 |
| Ixinity2000iu · For Injection | Coagulation factor ix | United States | Not marketed | 2015 |
| Ixinity1000iu · For Injection | Coagulation factor ix | United States | Marketed | 2015 |
| Ixinity250iu · For Injection | Coagulation factor ix | United States | Not marketed | 2015 |
| Ixinity3000iu · For Injection | Coagulation factor ix | United States | Marketed | 2015 |
| Ixinity500iu · For Injection | Coagulation factor ix | United States | Not marketed | 2015 |
| Ixinity1500iu · For Injection | Coagulation factor ix | United States | Marketed | 2015 |
| METOJECT SUBCUTANEOUS22.5 mg / 0.45 ml · Solution | Methotrexate | Canada | Marketed | 2016 |
| METOJECT SUBCUTANEOUS17.5 mg / 0.35 ml · Solution | Methotrexate | Canada | Marketed | 2016 |
| METOJECT SUBCUTANEOUS12.5 mg / 0.25 ml · Solution | Methotrexate | Canada | Marketed | 2019 |
| METOJECT SUBCUTANEOUS25 mg / 0.5 ml · Solution | Methotrexate | Canada | Marketed | 2016 |
| METOJECT SUBCUTANEOUS10 mg / 0.2 ml · Solution | Methotrexate | Canada | Marketed | 2019 |
| METOJECT SUBCUTANEOUS15 mg / 0.3 ml · Solution | Methotrexate | Canada | Marketed | 2018 |
| METOJECT SUBCUTANEOUS20 mg / 0.4 ml · Solution | Methotrexate | Canada | Marketed | 2016 |
| METOJECT SUBCUTANEOUS7.5 mg / 0.15 ml · Solution | Methotrexate | Canada | Authorised | |
| OTIXAL0.3 % / w/v + 0.025 % / w/v · Solution | Ciprofloxacin, Fluocinolone acetonide | Canada | Marketed | 2017 |
| PEDIAPHARM NAPROXEN SUSPENSION25 mg / ml · Suspension | Naproxen | Canada | Marketed | 1996 |
| RASUVO10mg/0.20ml (10mg/0.20ml) | 12.5mg/0.25ml (12.5mg/0.25ml) | 15mg/0.30ml (15mg/0.30ml) | 17.5mg/0.35ml (17.5mg/0.35ml) | 20mg/0.4ml (20mg/0.4ml) | 22.5mg/0.45ml (22.5mg/0.45ml) | 25mg/0.5ml (25mg/0.5ml) | 27.5mg/0.55ml (27.5mg/0.55ml) | 30mg/0.6ml (30mg/0.6ml) | 7.5mg/0.15ml (7.5mg/0.15ml) · Solution | Methotrexate | United States | Marketed | 2014 |
| RELAXA100 % · Powder For Solution | Macrogol | Canada | Marketed | 2010 |
| RUPALL10 mg · Tablet | Rupatadine | Canada | Marketed | 2017 |
| RUPALL1 mg / ml · Solution | Rupatadine | Canada | Marketed | 2017 |
| TRECONDYV1 g / vial · Powder | Treosulfan | Canada | Authorised | |
| TRECONDYV5 g / vial · Powder | Treosulfan | Canada | Marketed | 2021 |